Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Acquisition brings leading sickle cell disease portfolio and pipeline including Oxbryta® (voxelotor), a first-in-class medicine that directly targets the root cause of SCD, to Pfizer with potential to address critical needs in an underserved patient community.
Lead Product(s): Voxelotor
Therapeutic Area: Genetic Disease Product Name: Oxbryta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $5,400.0 million Upfront Cash: $5,400.0 million
Deal Type: Acquisition October 05, 2022
Details:
Proposed acquisition drives growth by bringing leading sickle cell disease expertise and rare hematology portfolio and pipeline of GBT including Oxbryta (voxelotor) tablets for treatment of sickle cell disease (SCD) and GBT601.
Lead Product(s): Voxelotor
Therapeutic Area: Hematology Product Name: Oxbryta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $5,400.0 million Upfront Cash: $5,400.0 million
Deal Type: Acquisition August 08, 2022
Details:
Oxbryta (Voxelotor) works by increasing hemoglobin’s affinity for oxygen, inhibits sickle hemoglobin polymerization and resultant sickling and destruction of red blood cells leading to hemolysis and anemia, are primary pathologies faced by every single person living with SCD.
Lead Product(s): Voxelotor
Therapeutic Area: Genetic Disease Product Name: Oxbryta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2022
Details:
GBT021601 (GBT601) has the same mechanism of action as Oxbryta (voxelotor), with the potential for improved clinical results by achieving higher hemoglobin levels and occupancy at a lower dose.
Lead Product(s): GBT601
Therapeutic Area: Genetic Disease Product Name: GBT021601
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
Oxbryta (voxelotor) is an oral, once-daily therapy for patients with sickle cell disease (SCD). Oxbryta works by increasing hemoglobin’s affinity for oxygen.
Lead Product(s): Voxelotor
Therapeutic Area: Genetic Disease Product Name: Oxbryta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
GBT021601 (GBT601) is being studied in a single and multiple ascending dose Phase 1 study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of GBT601 in patients with SCD ages 18 to 60 years.
Lead Product(s): GBT601
Therapeutic Area: Genetic Disease Product Name: GBT021601
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
Data from Phase 1 studies of GBT021601 (GBT601), company’s next generation sickle hemoglobin (HbS) polymerization inhibitor, showed promise in the clinic, with Multiple daily doses were well tolerated in both healthy volunteers and adult SCD patients.
Lead Product(s): GBT601
Therapeutic Area: Genetic Disease Product Name: GBT021601
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
The first sickle hemoglobin polymerization inhibitor approved in Europe, Oxbryta increases hemoglobin levels and reduces sickling and hemolysis – the cause of long-term complications of sickle cell disease.
Lead Product(s): Voxelotor
Therapeutic Area: Genetic Disease Product Name: Oxbryta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2022
Details:
This positive opinion means that those patients living with SCD and meeting the eligibility criteria can gain early, pre-license access to voxelotor, while the MHRA completes its review of the Marketing Authorisation Application (MAA).
Lead Product(s): Voxelotor
Therapeutic Area: Genetic Disease Product Name: Oxbryta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2022
Details:
The FDA’s approval of the sNDA is based on data from the open-label Phase 2a HOPE-KIDS 1 Study, which showed that weight-based treatment with the dispersible tablet formulation of Oxbryta (Voxelotor) resulted in rapid and sustained improvements in hemoglobin.
Lead Product(s): Voxelotor
Therapeutic Area: Genetic Disease Product Name: Oxbryta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2021